Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors.
The content of urokinase and tissue plasminogen activators and their inhibitor PAI-1 in tumors and histologically intact tissues from patients with breast, ovarian, and non-small-cell lung cancer was measured by enzyme immunoassay. The content of urokinase plasminogen activator and PAI-1 considerably increased in all malignant tumors, however the correlation between the expression of components of the plasminogen activation system and clinical morphological feature and prognosis of the disease depends on the type of tumor.
Gershtein
E S
ES
N. N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences. es-gershtein@mtu-net.ru
Kushlinskii
N E
NE
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000378:metabolism*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000378:metabolism*; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism*; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors / Q000097:blood / Q000378:metabolism; D015842:Serine Proteinase Inhibitors / Q000378:metabolism; D010959:Tissue Plasminogen Activator / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors / Q000097:blood / Q000378:metabolism*
D017395:Plasminogen Activator Inhibitor 1; D015842:Serine Proteinase Inhibitors; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator